Category - Markets

Leerink upgraded for Dova Pharmaceuticals (NASDAQ:DOVA) to “outperform” from “market perform” and raised its price target to $32 from $24 after competitor, Shionogi, announced results from a Phase 3 trial. Shares of...

Roth Capital Partners launched coverage of AIT Therapeutics (OTC:AITB) with a “buy” rating and $14 price target. The stock closed at $5.75 on Sept. 25. AIT is utilizing nitric oxide-based inhalation technology to treat...

Stifel downgraded Genocea Biosciences (NASDAQ:GNCA) to “hold” from “buy” and slashed its price target to $2.50 from $15 after the company shifted its strategic focus. The stock closed at $5.33 on Sept. 25. “We believe...

Canaccord Genuity upgraded STAAR Surgical (NASDAQ:STAA) to “buy” from “hold” and raised its price target to $15 from $11, suggesting a resolution to a FDA warning letter soon. The stock closed at $10.90 on Sept. 22...

William Blair upgraded Akari Therapeutics (NASDAQ:AKTX) to “outperform” from “market perform” after the company announced that, following its end-of-Phase-2 meeting with the FDA, it is advancing Coversin for the...

Profound Medical (TSXV:PRN; OTCQX:PRFMF) closed a bought deal financing for total proceeds of $10-million. The company sold 10 million units at a price of $1 each, with each unit consisting of one common share of...

Mackie Research downgraded Helius Medical Technologies (TSX:HSM) to “hold” from “speculative buy,” but maintained its price target of $2.70 (Canadian). The stock closed at $3.50 on Sept. 19.

Mackie Research Capital initiated coverage of Promis Neurosciences (TSX:PMN) with a “speculative buy” rating and price target of 50 cents, saying the company has a promising new path to target Alzheimer’s disease (AD)...

Leerink launched coverage of Synlogic (NASDAQ:SYBX) with an “outperform” rating and $25 price target. The stock closed at $18.73 on Sept. 18. Synlogic is a leader in the potentially revolutionary field of synthetic...

William Blair upgraded Arrowhead Pharmaceuticals (NASDAQ:ARWR) to “outperform” from “market perform” and raised its fair value estimate to $6 from $2 after the company’s R&D day on Sept. 14. The stock closed at $3...